Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
October 2012

Lurasidone (Latuda) in Context
The new antipsychotic lurasidone (Latuda) may cause less weight gain than other second-generation antipsychotics but may not be the most efficacious treatment for patients with schizophrenia.

Antidepressants and Acute Angle-Closure Glaucoma
Recent use of antidepressants appears to increase the risk of acute angle-closure glaucoma in elderly patients.

Clozapine Can Prevent Suicide
An increased use of clozapine (Clozaril and others) to treat schizophrenia would prevent more suicides than the number of deaths that would be caused by its adverse events.

In Brief
Obesity and Metabolic Abnormalities in Midlife Associated with Later Cognitive Decline; EMR Practices Provide Less Depression Treatment for Patients with More Complex Conditions

Doctors Overestimate Patient Adherence to Antipsychotics
In a recent survey, physicians were correct about the level of treatment adherence for only about half of their patients.

Osteoporosis, Fracture Risk, and Schizophrenia
Data suggest that both schizophrenia and the drugs used to treat it increase the risk of fractures by causing osteoporosis.

Osteoporosis, Fracture Risk, and Schizophrenia

October 2012

Osteoporosis is an abnormally low bone mineral density (BMD). It has been reported to occur more often in people with schizophrenia than in the general population. Kishimoto and others conducted a review of studies on BMD, osteoporosis, and fracture risk in people with schizophrenia.1

Of…

To view the rest of this article, please: